课题基金 / 基金详情

Sex-dependent effects of cannabis: Assessing abuse-related and pharmacokinetic differences between men and women

Sex-dependent effects of cannabis: Assessing abuse-related and pharmacokinetic differences between men and women
大麻的性别依赖性影响:评估男性和女性之间滥用相关和药代动力学的差异
批准号:
10810597
负责人:
ZIVA D COOPER
金额:
$7.04万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-09-15 至 2025-06-30

项目摘要

项目成果

ZIVA D COOPER的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 (家长奖) 在美国,大麻使用障碍(CUD)的比率在过去十年中翻了一番。虽然 越来越多的女性总体吸食大麻和吸食大麻的比例仍然低于男性。然而, 流行病学报告记录了伸缩效应;妇女从首次使用到CUD的过渡速度更快 比男人更快。对实验室动物进行的临床前研究表明,相对于雄性,雌性 对大麻素的强化作用更敏感,也许可以解释 CUD在流行病学报告中观察到。到目前为止,还没有研究前瞻性地探索大麻的性别- 人类在虐待责任方面的不同。为了了解大麻的急性影响, 在女性中观察到CUD的加速轨迹,建议的研究将比较剂量依赖关系 吸烟大麻对直接与滥用有关的终点的影响--轻-重-之间的责任- 使用大麻的男性和女性,包括积极的主观影响和大麻自我管理。在……里面 除了与滥用有关的终点外,了解吸烟止痛反应中的性别差异 大麻对公共卫生有重大影响。近50%的医用大麻使用者是女性, 疼痛被认为是寻求治疗的主要适应症。因此,评估这两种滥用 大麻的易感性和止痛效果与性别有关,这一点至关重要。 临床前研究指出,对Δ-9的性别依赖性反应有三个因素: 四氢大麻酚(THC)和其他大麻素1受体(CBR1)激动剂;1)雌二醇增加 对CBR1激动剂滥用相关效应的敏感性,2)THC的药代动力学(PK)随女性不同 表现出比男性更快地从THC转化为其主要精神活性代谢物,以及3)增强 慢性应激后女性对抗伤害效应(但不包括其他终点)的耐受性 行政管理。拟议的前瞻性临床研究将直接解决性别依赖在 大麻的影响作为这些因素的函数。我们将1)比较与滥用相关的和止痛效果 在控制月经周期影响的情况下,男性与女性之间吸烟的大麻,2)评估差异 在男性和女性之间的THC和相应代谢物的PK中,以及3)调查大麻的性行为- 依赖效应是大麻使用频率的函数(少量吸食大麻与大量吸食大麻)。具体来说, 健康的轻度(N=60,30M,30F)和重度(N=60,30M,30F)大麻使用者将被招募参加这三个疗程, 双盲、安慰剂对照的实验室研究。所有参与者都将服用安慰剂(0%THC), 大麻的低浓度(3%THC)和高强度(10%THC)按平衡顺序排列。大麻的滥用- 相关效应、止痛和药代动力学将作为性别和频率的函数进行评估。 吸食大麻。这项研究的发现将填补我们知识中的一个关键空白,并将是完整的
英文摘要
Project Summary (Parent Award) Rates of Cannabis Use Disorder (CUD) have doubled over the last ten years in the US. Although increasing, overall rates of cannabis use and CUD are still lower among women relative to men. However, epidemiological reports document a telescoping effect; women transition from first use to CUD at a faster rate than men. Preclinical studies with laboratory animals demonstrate that relative to males, females are more sensitive to the reinforcing effects of cannabinoids, perhaps explaining the accelerated progression to CUD observed in the epidemiological reports. To date, no studies have prospectively probed cannabis’s sex- dependent differences in abuse-liability in humans. To understand cannabis’s acute effects that underlie the accelerated trajectory to CUD observed in women, the proposed study will compare the dose-dependent effects of smoked cannabis on endpoints directly associated with abuse-liability between light- and heavy- cannabis using men and women, including positive subjective effects and cannabis self-administration. In addition to abuse-related endpoints, understanding sex differences in the analgesic responses to smoked cannabis have significant public health implications. Nearly 50% of medical cannabis users are women, with pain cited as the primary indication for which treatment is sought. Thus, assessing both the abuse liability and analgesic efficacy of cannabis as a function of sex is of critical importance. Preclinical studies point to three factors that contribute to sex-dependent responses to Δ-9- tetrahydrocannabinol (THC) and other cannabinoid 1 receptor (CBR1) agonists; 1) estradiol increases the sensitivity to CBR1 agonist abuse-related effects, 2) pharmacokinetics (pK) of THC differ, with females exhibiting faster conversion from THC to its primary psychoactive metabolite than males and 3) enhanced development of tolerance to the antinociceptive effects (but not other endpoints) in females after chronic administration. The proposed prospective clinical study will directly address sex-dependent differences in cannabis’s effects as a function of these factors. We will 1) compare the abuse-related and analgesic effects of smoked cannabis between men to women while controlling for menstrual cycle effects, 2) evaluate differences in the pK of THC and respective metabolites between men and women, and 3) investigate cannabis’s sex- dependent effects as a function of frequency of cannabis use (light versus heavy cannabis users). Specifically, healthy light (N=60, 30M, 30F) and heavy (N=60, 30M, 30F) cannabis users will be recruited for this 3-session, double-blind, placebo-controlled, laboratory study. All participants will be administered placebo (0% THC), lower (3% THC), and higher (10% THC) strengths of cannabis in counter- balanced order. Cannabis’s abuse- related effects, analgesia, and pharmacokinetics will be assessed as a function of sex and frequency of cannabis use. Findings from this study will fill a critical gap in our knowledge and be integral
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1055/a-1749-5391
发表时间: 2022-05
期刊: Geburtshilfe und Frauenheilkunde
影响因子: 2.7
作者: []
通讯作者:
Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies.
在评估镇痛功效时考虑大麻和大麻衍生产品的滥用倾向和神经认知影响:随机对照研究的全面回顾。
DOI: 10.1080/00952990.2019.1669628
发表时间: 2019
期刊: The American journal of drug and alcohol abuse
影响因子: --
作者: [Cooper,ZivaD, Abrams,DonaldI]
通讯作者: Abrams,DonaldI
Understanding Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration in the Era of Legalization.
了解合法化时代美国退伍军人健康管理局的大麻使用障碍诊断。
DOI: 10.1176/appi.ajp.20220675
发表时间: 2022
期刊: The American journal of psychiatry
影响因子: --
作者: [Lake,Stephanie, Cooper,ZivaD]
通讯作者: Cooper,ZivaD
DOI: 10.1080/00952990.2021.1946071
发表时间: 2021-09-03
期刊: AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
影响因子: 2.7
作者: [Kozak, Karolina, Smith, Philip H., Lowe, Darby J. E., Weinberger, Andrea H., Cooper, Ziva D., Rabin, Rachel A., George, Tony P.]
通讯作者: George, Tony P.
Age-and sex-dependent pharmacodynamics and pharmacokinetics of oral and smoked delta-9-THC
Age-and sex-dependent pharmacodynamics and pharmacokinetics of oral and smoked delta-9-THC
海外基金